Related Experiment Video
Updated: Dec 11, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Protease Inhibitor Use in COVID-19
Yueqi Song1, Wujian Peng2, Donge Tang1
1Clinical Medical Research Center, The Second Clinical Medical College of Jinan University (Shenzhen People's Hospital), 1017 North Road, Dongmen, Shenzhen, 518020 Guangdong People's Republic of China.
This study offers guidance on diagnosing, treating, and preventing Coronavirus Disease 2019 (COVID-19) based on frontline experiences. Lopinavir/ritonavir is suggested for antiviral treatment, though more clinical data is needed for definitive proof of efficacy.
Area of Science:
- Infectious Diseases
- Public Health
- Virology
Background:
- The Coronavirus Disease 2019 (COVID-19) pandemic has significantly impacted global health and livelihoods.
- Frontline healthcare professionals face unprecedented challenges in managing COVID-19 patients.
Purpose of the Study:
- To provide evidence-based recommendations for the diagnosis, treatment, and prevention of COVID-19.
- To share clinical insights and experiences from a hospital actively treating COVID-19 patients.
Main Methods:
- Review of the latest reports and scientific literature on COVID-19.
- Consolidation of clinical experience from doctors treating COVID-19 patients.
- Analysis of the efficacy of lopinavir/ritonavir in treating COVID-19, MERS, and SARS.
Main Results:
- Lopinavir/ritonavir is proposed as a potential antiviral treatment for COVID-19 based on preliminary experience.
- Successful use of lopinavir/ritonavir in treating Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) provides a basis for its consideration in COVID-19.
- Further clinical data is required to substantiate the efficacy of lopinavir/ritonavir for COVID-19 treatment.
Conclusions:
- The study offers practical suggestions for managing the COVID-19 epidemic.
- Lopinavir/ritonavir shows promise as an antiviral therapy for COVID-19, warranting further investigation.
- A need for more robust clinical evidence to confirm the effectiveness of lopinavir/ritonavir against COVID-19 is highlighted.
More Related Videos
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Subviral Agents
Pharmacokinetics: Drug–Food and Drug–Viral Interactions

